This page has only limited features, please log in for full access.
Pam R. Taub, MD, FACC, is Associate Professor of Medicine in the Division of Cardiovascular Medicine, Department of Medicine, at the University of California (UC), San Diego. She is also the founder and Director of the Step Family Foundation Cardiovascular Rehabilitation and Wellness Center. Her clinical practice focuses on preventive cardiology, lipidology, as well as women's cardiovascular health. She is active in clinical/translational research and has received funding from the National Institutes of Health (Principal Investigator on R01 grant), Department of Defense, and American Heart Association. Her research focuses on assessing the impact of pharmacologic intervention and lifestyle changes on cardiometabolic disease. She is conducting research studies evaluating biomarkers for cardiovascular risk factor stratification, studying the effects of daily fasting in improving cardiometabolic parameters and examining the effects of a compound in dark chocolate (epicatechin) on mitochondrial function/cellular bioenergetics and exercise capacity, Dr. Taub is widely published and has authored numerous publications in top peer-reviewed journals. Dr. Taub received her MD from Boston University School of Medicine. She completed her residency in internal medicine at the University of Washington Medical Center in Seattle and her fellowship in cardiovascular medicine at UC San Diego. She is board certified in internal medicine, cardiovascular disease,.
A 32-year-old woman with a history of symptomatic supraventricular tachycardia, inappropriate sinus tachycardia, and hyperadrenergic POTS was treated with ivabradine and metoprolol. She then presented with bradycardia and Mobitz II second-degree AV block on event monitoring six weeks after COVID-19 infection. Her post-viral workup revealed normalization of catecholamine levels and significant symptomatic improvement in heart rate. To the authors’ knowledge, this is the first reported case of improvement in POTS after COVID-19 infection. As our understanding of COVID-19 continues to improve, it will be vital to better understand the impact of COVID-19 dysautonomia on cardiac patients.
Rebecca A. Ocher; Erika Padilla; Jonathan C. Hsu; Pam R. Taub. Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection. Case Reports in Cardiology 2021, 2021, 1 -3.
AMA StyleRebecca A. Ocher, Erika Padilla, Jonathan C. Hsu, Pam R. Taub. Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection. Case Reports in Cardiology. 2021; 2021 ():1-3.
Chicago/Turabian StyleRebecca A. Ocher; Erika Padilla; Jonathan C. Hsu; Pam R. Taub. 2021. "Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection." Case Reports in Cardiology 2021, no. : 1-3.
Despite awareness by health-care providers that diet impacts cardiovascular health, there remains a knowledge gap in how to evaluate the impact in an objective way. This chapter discusses the use of novel and clinically relevant biomarkers to quantitatively and objectively assess cardiac risk for different dietary patterns. Data will be presented on how plant-based eating patterns that limit red meat consumption (e.g. Mediterranean diet) promote cardiovascular health and improve cardiovascular biomarkers such as LDL and HDL, Hs-CRP, Trimethylamine N-oxide (TMAO), and vitamin D.
Cameron K. Ormiston; Rebecca Ocher; Pam R. Taub. Impact of Nutrition on Biomarkers of Cardiovascular Health. Contemporary Cardiology 2021, 29 -45.
AMA StyleCameron K. Ormiston, Rebecca Ocher, Pam R. Taub. Impact of Nutrition on Biomarkers of Cardiovascular Health. Contemporary Cardiology. 2021; ():29-45.
Chicago/Turabian StyleCameron K. Ormiston; Rebecca Ocher; Pam R. Taub. 2021. "Impact of Nutrition on Biomarkers of Cardiovascular Health." Contemporary Cardiology , no. : 29-45.
Purpose of review To summarize recent innovations in cardiac rehabilitation and provide a view towards the future of cardiac rehabilitation as it adjusts to the pressures of a global pandemic. Recent findings Although cardiac rehabilitation has been shown to result in a mortality benefit, research continues to enumerate the benefits of cardiac rehabilitation to patient function and quality of life in a growing range of cardiovascular diseases. In addition, new methodologies and new models of cardiac rehabilitation have emerged with the goal of increasing patient referral and participation. Summary Cardiac rehabilitation continues to evolve and adapt to serve a growing and diversifying number of patients with cardiovascular disease with the goal of both decreasing mortality and improving patient function.
Elizabeth Epstein; Sofie Maisel; Kathryn Maysent; Pam R. Taub. Cardiac rehabilitation for coronary artery disease: latest updates. Current Opinion in Cardiology 2021, 36, 556 -564.
AMA StyleElizabeth Epstein, Sofie Maisel, Kathryn Maysent, Pam R. Taub. Cardiac rehabilitation for coronary artery disease: latest updates. Current Opinion in Cardiology. 2021; 36 (5):556-564.
Chicago/Turabian StyleElizabeth Epstein; Sofie Maisel; Kathryn Maysent; Pam R. Taub. 2021. "Cardiac rehabilitation for coronary artery disease: latest updates." Current Opinion in Cardiology 36, no. 5: 556-564.
Pam R. Taub; Adena Zadourian; Jonathan C. Hsu. Reply. Journal of the American College of Cardiology 2021, 77, 3142 -3143.
AMA StylePam R. Taub, Adena Zadourian, Jonathan C. Hsu. Reply. Journal of the American College of Cardiology. 2021; 77 (24):3142-3143.
Chicago/Turabian StylePam R. Taub; Adena Zadourian; Jonathan C. Hsu. 2021. "Reply." Journal of the American College of Cardiology 77, no. 24: 3142-3143.
Patients with underlying cardiovascular conditions are particularly vulnerable to severe COVID-19. In this project, we aimed to characterize similarities in dysregulated immune pathways between COVID-19 patients and patients with cardiomyopathy, venous thromboembolism (VTE), or coronary artery disease (CAD). We hypothesized that these similarly dysregulated pathways may be critical to how cardiovascular diseases (CVDs) exacerbate COVID-19. To evaluate immune dysregulation in different diseases, we used four separate datasets, including RNA-sequencing data from human left ventricular cardiac muscle samples of patients with dilated or ischemic cardiomyopathy and healthy controls; RNA-sequencing data of whole blood samples from patients with single or recurrent event VTE and healthy controls; RNA-sequencing data of human peripheral blood mononuclear cells (PBMCs) from patients with and without obstructive CAD; and RNA-sequencing data of platelets from COVID-19 subjects and healthy controls. We found similar immune dysregulation profiles between patients with CVDs and COVID-19 patients. Interestingly, cardiomyopathy patients display the most similar immune landscape to COVID-19 patients. Additionally, COVID-19 patients experience greater upregulation of cytokine- and inflammasome-related genes than patients with CVDs. In all, patients with CVDs have a significant overlap of cytokine- and inflammasome-related gene expression profiles with that of COVID-19 patients, possibly explaining their greater vulnerability to severe COVID-19.
Abby Lee; Grant Castaneda; Wei Li; Chengyu Chen; Neil Shende; Jaideep Chakladar; Pam Taub; Eric Chang; Weg Ongkeko. COVID-19 Severity Potentially Modulated by Cardiovascular-Disease-Associated Immune Dysregulation. Viruses 2021, 13, 1018 .
AMA StyleAbby Lee, Grant Castaneda, Wei Li, Chengyu Chen, Neil Shende, Jaideep Chakladar, Pam Taub, Eric Chang, Weg Ongkeko. COVID-19 Severity Potentially Modulated by Cardiovascular-Disease-Associated Immune Dysregulation. Viruses. 2021; 13 (6):1018.
Chicago/Turabian StyleAbby Lee; Grant Castaneda; Wei Li; Chengyu Chen; Neil Shende; Jaideep Chakladar; Pam Taub; Eric Chang; Weg Ongkeko. 2021. "COVID-19 Severity Potentially Modulated by Cardiovascular-Disease-Associated Immune Dysregulation." Viruses 13, no. 6: 1018.
Irvin Xu; Pam R. Taub. Baseline testosterone level may modulate statin efficacy. Coronary Artery Disease 2021, Publish Ah, 1 .
AMA StyleIrvin Xu, Pam R. Taub. Baseline testosterone level may modulate statin efficacy. Coronary Artery Disease. 2021; Publish Ah ():1.
Chicago/Turabian StyleIrvin Xu; Pam R. Taub. 2021. "Baseline testosterone level may modulate statin efficacy." Coronary Artery Disease Publish Ah, no. : 1.
The COVID-19 pandemic has forced many center-based cardiac rehabilitation (CBCR) programs to close or limit their usual offerings. In order for patients to continue to benefit from CR, programs need to rapidly adapt to the current environment. This review highlights ways CR has evolved, and reviews the history of CR and recent advancements in telemedicine including remote patient monitoring, and mobile health that can be applied to CR. Despite that initial studies indicate that home-based CR (HBCR) is safe and effective, HBCR has faced several challenges that have prevented it from becoming more widely implemented. Many previous concerns can now be addressed through the use of new innovations in home-based healthcare delivery. Since its inception, CR has become increasingly recognized as an important tool to improve patient mortality and quality of life in a broad range of cardiac diseases. While there has been little need to modify the delivery of CR since the 1950s, COVID-19 now serves as the necessary impetus to make HBCR an equal alternative to CBCR.
Elizabeth Epstein; Neeja Patel; Kathryn Maysent; Pam R. Taub. Cardiac Rehab in the COVID Era and Beyond: mHealth and Other Novel Opportunities. Current Cardiology Reports 2021, 23, 1 -8.
AMA StyleElizabeth Epstein, Neeja Patel, Kathryn Maysent, Pam R. Taub. Cardiac Rehab in the COVID Era and Beyond: mHealth and Other Novel Opportunities. Current Cardiology Reports. 2021; 23 (5):1-8.
Chicago/Turabian StyleElizabeth Epstein; Neeja Patel; Kathryn Maysent; Pam R. Taub. 2021. "Cardiac Rehab in the COVID Era and Beyond: mHealth and Other Novel Opportunities." Current Cardiology Reports 23, no. 5: 1-8.
Postural orthostatic tachycardia syndrome (POTS) is a complex, multifaceted disorder that impairs functional status and quality of life. Current pharmacological treatments are limited. This study investigated the effect of ivabradine (selective blocker of the Ifunny channel in the sinoatrial node) on heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels in patients with hyperadrenergic POTS defined by plasma NE >600 pg/ml and abnormal tilt table test. In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were crossed over to the other treatment for 1 month. Heart rate, QOL, and plasma NE levels were measured at baseline and at the end of each treatment month. The average age was 33.9 ± 11.7 years, 95.5% were women (n = 21), and 86.4% were White (n = 23). There was a significant reduction in heart rate between placebo and ivabradine (p < 0.001). Patients reported significant improvements in QOL with RAND 36-Item Health Survey 1.0 for physical functioning (p = 0.008) and social functioning (p = 0.021). There was a strong trend in reduction of NE levels upon standing with ivabradine (p = 0.056). Patients did not experience any significant side-effects, such as bradycardia or hypotension, with ivabradine. Ivabradine is safe and effective in significantly improving heart rate and QOL in patients with hyperadrenergic POTS as the predominant subtype.
Pam R. Taub; Adena Zadourian; Hannah C. Lo; Cameron K. Ormiston; Shahrokh Golshan; Jonathan C. Hsu. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. Journal of the American College of Cardiology 2021, 77, 861 -871.
AMA StylePam R. Taub, Adena Zadourian, Hannah C. Lo, Cameron K. Ormiston, Shahrokh Golshan, Jonathan C. Hsu. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. Journal of the American College of Cardiology. 2021; 77 (7):861-871.
Chicago/Turabian StylePam R. Taub; Adena Zadourian; Hannah C. Lo; Cameron K. Ormiston; Shahrokh Golshan; Jonathan C. Hsu. 2021. "Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome." Journal of the American College of Cardiology 77, no. 7: 861-871.
Metabolic syndrome (MetS) and erratic eating patterns are associated with circadian rhythm disruption which contributes to an increased cardiometabolic risks. Restricting eating period (time-restricted eating, TRE) can restore robust circadian rhythms and improve cardiometabolic health. We describe a protocol of the Time-Restricted Eating on Metabolic and Neuroendocrine homeostasis, Inflammation, and Oxidative Stress (TREMNIOS) pilot clinical trial in Polish adult patients with MetS and eating period of ≥14 h/day. The study aims to test the feasibility of TRE intervention and methodology for evaluating its efficacy for improving metabolic, neuroendocrine, inflammatory, oxidative stress and cardiac biomarkers, and daily rhythms of behavior for such population. Participants will apply 10-h TRE over a 12-week monitored intervention followed by a 12-week self-directed intervention. Changes in eating window, body weight and composition, biomarkers, and rhythms of behavior will be evaluated. Dietary intake, sleep, activity and wellbeing will be monitored with the myCircadianClock application and questionnaires. Adherence to TRE defined as the proportion of days recorded with app during the monitored intervention in which participants satisfied 10-h TRE is the primary outcome. TREMNIOS will also provide an exploratory framework to depict post-TRE changes in cardiometabolic outcomes and behavior rhythms. This protocol extends previous TRE-related protocols by targeting European population with diagnosed MetS and including long-term intervention, validated tools for monitoring dietary intake and adherence, and comprehensive range of biomarkers. TREMNIOS trial will lay the groundwork for a large-scale randomized controlled trial to determine TRE efficacy for improving cardiometabolic health in MetS population.
Iwona Świątkiewicz; Celestyna Mila-Kierzenkowska; Alina Woźniak; Karolina Szewczyk-Golec; Jarosław Nuszkiewicz; Joanna Wróblewska; Paweł Rajewski; Simone Eussen; Kristine Færch; Emily Manoogian; Satchidananda Panda; Pam Taub. Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome. Nutrients 2021, 13, 346 .
AMA StyleIwona Świątkiewicz, Celestyna Mila-Kierzenkowska, Alina Woźniak, Karolina Szewczyk-Golec, Jarosław Nuszkiewicz, Joanna Wróblewska, Paweł Rajewski, Simone Eussen, Kristine Færch, Emily Manoogian, Satchidananda Panda, Pam Taub. Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome. Nutrients. 2021; 13 (2):346.
Chicago/Turabian StyleIwona Świątkiewicz; Celestyna Mila-Kierzenkowska; Alina Woźniak; Karolina Szewczyk-Golec; Jarosław Nuszkiewicz; Joanna Wróblewska; Paweł Rajewski; Simone Eussen; Kristine Færch; Emily Manoogian; Satchidananda Panda; Pam Taub. 2021. "Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome." Nutrients 13, no. 2: 346.
Metabolic syndrome (MetS) occurs in ~30% of adults and is associated with increased risk of cardiovascular disease and diabetes mellitus. MetS reflects the clustering of individual cardiometabolic risk factors including central obesity, elevated fasting plasma glucose, dyslipidemia, and elevated blood pressure. Erratic eating patterns such as eating over a prolonged period per day and irregular meal timing are common in patients with MetS. Misalignment between daily rhythms of food intake and circadian timing system can contribute to circadian rhythm disruption which results in abnormal metabolic regulation and adversely impacts cardiometabolic health. Novel approaches which aim at restoring robust circadian rhythms through modification of timing and duration of daily eating represent a promising strategy for patients with MetS. Restricting eating period during a day (time-restricted eating, TRE) can aid in mitigating circadian disruption and improving cardiometabolic outcomes. Previous pilot TRE study of patients with MetS showed the feasibility of TRE and improvements in body weight and fat, abdominal obesity, atherogenic lipids, and blood pressure, which were observed despite no overt attempt to change diet quantity and quality or physical activity. The present article aims at giving an overview of TRE human studies of individuals with MetS or its components, summarizing current clinical evidence for improving cardiometabolic health through TRE intervention in these populations, and presenting future perspectives for an implementation of TRE to treat and prevent MetS. Previous TRE trials laid the groundwork and indicate a need for further clinical research including large-scale controlled trials to determine TRE efficacy for reducing long-term cardiometabolic risk, providing tools for sustained lifestyle changes and, ultimately, improving overall health in individuals with MetS.
Iwona Świątkiewicz; Alina Woźniak; Pam Taub. Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives. Nutrients 2021, 13, 221 .
AMA StyleIwona Świątkiewicz, Alina Woźniak, Pam Taub. Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives. Nutrients. 2021; 13 (1):221.
Chicago/Turabian StyleIwona Świątkiewicz; Alina Woźniak; Pam Taub. 2021. "Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives." Nutrients 13, no. 1: 221.
Cardiovascular disease (CVD) has been the leading cause of death for the past 20 years and is projected to continue to increase in the coming years as the population ages and the prevalence of obesity and type 2 diabetes increases. Preventive and disease-modifying therapies continue to develop, which reduces CVD mortality, but perpetuates people living with established CVD. Secondary prevention treatments are needed to improve quality of life and reduce adverse outcomes in this growing population. Effective treatments for these diseases include lifestyle modification therapies such as exercise, nutrition, and stress management. In patients with CVD, these behavioral interventions have been shown to reduce risk of hospital readmissions, reduce recurrent cardiovascular events, and improve patients’ quality of life. These topics are explored further in this chapter. These components synergistically work together in cardiac rehabilitation (CR) programs to reduce CVD outcomes, with different types of programs providing varying levels of lifestyle modifications. These programs are unique in that they can provide structured, monitored exercise and behavioral counselling and are covered by most insurers. Though these programs have been proven effective, they are still underutilized in countries around the world. Major barriers include low referral rates, lack of understanding the importance of CR, and difficulty attending the programs. Greater awareness and advocacy is needed from both patients and providers to connect the people who need it the most.
Hannah C. Lo; Aryana Pazargadi; Iwona Świątkiewicz; Pam Taub. Secondary Prevention and Cardiac Rehabilitation. Contemporary Cardiology 2020, 673 -703.
AMA StyleHannah C. Lo, Aryana Pazargadi, Iwona Świątkiewicz, Pam Taub. Secondary Prevention and Cardiac Rehabilitation. Contemporary Cardiology. 2020; ():673-703.
Chicago/Turabian StyleHannah C. Lo; Aryana Pazargadi; Iwona Świątkiewicz; Pam Taub. 2020. "Secondary Prevention and Cardiac Rehabilitation." Contemporary Cardiology , no. : 673-703.
Cardiovascular disease remains one of the most prevalent and preventable chronic conditions worldwide. Diet modification is the foundation of cardiovascular disease prevention. Several dietary approaches have emerged to promote better cardiovascular health. The rapid dissemination of anecdotal and observational data through the internet and social media has caused confusion amongst providers and patients. The aim of this comprehensive review is to present objective insights into 2 of today's most popular fad diets: ketogenic diet and intermittent fasting. We will evaluate the performance of these diets based on their impact on cardiovascular risk factors.
Melroy S. D'souza; Tiffany Dong; Gabrielle Ragazzo; Devinder Dhindsa; Anurag Mehta; Pratik B. Sandesara; Andrew M. Freeman; Pam Taub; Laurence S. Sperling. From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease. The American Journal of Medicine 2020, 133, 1126 -1134.
AMA StyleMelroy S. D'souza, Tiffany Dong, Gabrielle Ragazzo, Devinder Dhindsa, Anurag Mehta, Pratik B. Sandesara, Andrew M. Freeman, Pam Taub, Laurence S. Sperling. From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease. The American Journal of Medicine. 2020; 133 (10):1126-1134.
Chicago/Turabian StyleMelroy S. D'souza; Tiffany Dong; Gabrielle Ragazzo; Devinder Dhindsa; Anurag Mehta; Pratik B. Sandesara; Andrew M. Freeman; Pam Taub; Laurence S. Sperling. 2020. "From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease." The American Journal of Medicine 133, no. 10: 1126-1134.
Cardiac Rehabilitation (CR) was originally designed to return patients to their prior level of functioning after myocardial infarction (MI). Research has since revealed the mortality benefit of CR, and CR has been given a class 1A recommendation by the American Heart Association/American College of Cardiology (AHA/ACC). In this review, we shift our focus back to function and highlight the most recent research on the functional benefits of CR in a broad range of cardiac diseases and conditions. Currently, CR is indicated for patients with coronary artery disease (CAD), heart failure with reduced ejection fraction (HFrEF), peripheral arterial disease (PAD), transcatheter aortic valve replacement (TAVR), left ventricular assist devices (LVADs), and cardiac transplant. Among patients with those conditions, CR has been shown to improve exercise capacity, cognition, mental health, and overall quality of life. As survival of cardiac diseases increases, CR emerges as an increasingly important tool to lend quality to patients’ lives and therefore give meaning to survival.
Elizabeth Epstein; Ashley Rosander; Aryana Pazargadi; Pam Taub. Cardiac Rehab for Functional Improvement. Current Heart Failure Reports 2020, 17, 161 -170.
AMA StyleElizabeth Epstein, Ashley Rosander, Aryana Pazargadi, Pam Taub. Cardiac Rehab for Functional Improvement. Current Heart Failure Reports. 2020; 17 (4):161-170.
Chicago/Turabian StyleElizabeth Epstein; Ashley Rosander; Aryana Pazargadi; Pam Taub. 2020. "Cardiac Rehab for Functional Improvement." Current Heart Failure Reports 17, no. 4: 161-170.
In the United States, heart failure (HF) affects approximately 6.5 million adults. While studies show that individuals with HF often suffer from adverse symptoms such as depression and anxiety, studies also show that these symptoms can be at least partially offset by the presence of spiritual wellbeing. In a sample of 327 men and women with AHA/ACC classification Stage B HF, we found that more spirituality in patients was associated with better clinically-related symptoms such as depressed mood and anxiety, emotional variables (affect, anger), well-being (optimism, satisfaction with life), and physical health-related outcomes (fatigue, sleep quality). These patients also showed better self-efficacy to maintain cardiac function. Simply belonging to a religious organization independent of spiritualty, however, was not a reliable predictor of health-related benefits. In fact, we observed instances of belonging to a religious organization unaccompanied by parallel spiritual ratings, which appeared counterproductive.
Jesús Saiz; Meredith A. Pung; Kathleen L. Wilson; Christopher Pruitt; Thomas Rutledge; Laura Redwine; Pam R. Taub; Barry H. Greenberg; Paul J. Mills. Is Belonging to a Religious Organization Enough? Differences in Religious Affiliation Versus Self-Ratings of Spirituality on Behavioral and Psychological Variables in Individuals with Heart Failure. Healthcare 2020, 8, 129 .
AMA StyleJesús Saiz, Meredith A. Pung, Kathleen L. Wilson, Christopher Pruitt, Thomas Rutledge, Laura Redwine, Pam R. Taub, Barry H. Greenberg, Paul J. Mills. Is Belonging to a Religious Organization Enough? Differences in Religious Affiliation Versus Self-Ratings of Spirituality on Behavioral and Psychological Variables in Individuals with Heart Failure. Healthcare. 2020; 8 (2):129.
Chicago/Turabian StyleJesús Saiz; Meredith A. Pung; Kathleen L. Wilson; Christopher Pruitt; Thomas Rutledge; Laura Redwine; Pam R. Taub; Barry H. Greenberg; Paul J. Mills. 2020. "Is Belonging to a Religious Organization Enough? Differences in Religious Affiliation Versus Self-Ratings of Spirituality on Behavioral and Psychological Variables in Individuals with Heart Failure." Healthcare 8, no. 2: 129.
Acute ST-segment elevation myocardial infarction (STEMI) activates inflammation that can contribute to left ventricular systolic dysfunction (LVSD) and heart failure (HF). The objective of this study was to examine whether high-sensitivity C-reactive protein (CRP) concentration is predictive of long-term post-infarct LVSD and HF. In 204 patients with a first STEMI, CRP was measured at hospital admission, 24 h (CRP24), discharge (CRPDC), and 1 month after discharge (CRP1M). LVSD at 6 months after discharge (LVSD6M) and hospitalization for HF in long-term multi-year follow-up were prospectively evaluated. LVSD6M occurred in 17.6% of patients. HF hospitalization within a median follow-up of 5.6 years occurred in 45.7% of patients with LVSD6M vs. 4.9% without LVSD6M (p < 0.0001). Compared to patients without LVSD6M, the patients with LVSD6M had higher CRP24 and CRPDC and persistent CRP1M ≥ 2 mg/L. CRP levels were also higher in patients in whom LVSD persisted at 6 months (51% of all patients who had LVSD at discharge upon index STEMI) vs. patients in whom LVSD resolved. In multivariable analysis, CRP24 ≥ 19.67 mg/L improved the prediction of LVSD6M with an increased odds ratio of 1.47 (p < 0.01). Patients with LVSD6M who developed HF had the highest CRP during index STEMI. Elevated CRP concentration during STEMI can serve as a synergistic marker for risk of long-term LVSD and HF.
Iwona Świątkiewicz; Przemysław Magielski; Jacek Kubica; Adena Zadourian; Anthony N. DeMaria; Pam R. Taub. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. International Journal of Molecular Sciences 2020, 21, 807 .
AMA StyleIwona Świątkiewicz, Przemysław Magielski, Jacek Kubica, Adena Zadourian, Anthony N. DeMaria, Pam R. Taub. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. International Journal of Molecular Sciences. 2020; 21 (3):807.
Chicago/Turabian StyleIwona Świątkiewicz; Przemysław Magielski; Jacek Kubica; Adena Zadourian; Anthony N. DeMaria; Pam R. Taub. 2020. "Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure." International Journal of Molecular Sciences 21, no. 3: 807.
In animal models, time-restricted feeding (TRF) can prevent and reverse aspects of metabolic diseases. Time-restricted eating (TRE) in human pilot studies reduces the risks of metabolic diseases in otherwise healthy individuals. However, patients with diagnosed metabolic syndrome often undergo pharmacotherapy, and it has never been tested whether TRE can act synergistically with pharmacotherapy in animal models or humans. In a single-arm, paired-sample trial, 19 participants with metabolic syndrome and a baseline mean daily eating window of ≥14 h, the majority of whom were on a statin and/or antihypertensive therapy, underwent 10 h of TRE (all dietary intake within a consistent self-selected 10 h window) for 12 weeks. We found this TRE intervention improves cardiometabolic health for patients with metabolic syndrome receiving standard medical care including high rates of statin and anti-hypertensive use. TRE is a potentially powerful lifestyle intervention that can be added to standard medical practice to treat metabolic syndrome. Download : Download video (17MB)
Michael J. Wilkinson; Emily N.C. Manoogian; Adena Zadourian; Hannah Lo; Savannah Fakhouri; Azarin Shoghi; Xinran Wang; Jason Fleischer; Saket Navlakha; Satchidananda Panda; Pam R. Taub. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metabolism 2019, 31, 92 -104.e5.
AMA StyleMichael J. Wilkinson, Emily N.C. Manoogian, Adena Zadourian, Hannah Lo, Savannah Fakhouri, Azarin Shoghi, Xinran Wang, Jason Fleischer, Saket Navlakha, Satchidananda Panda, Pam R. Taub. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metabolism. 2019; 31 (1):92-104.e5.
Chicago/Turabian StyleMichael J. Wilkinson; Emily N.C. Manoogian; Adena Zadourian; Hannah Lo; Savannah Fakhouri; Azarin Shoghi; Xinran Wang; Jason Fleischer; Saket Navlakha; Satchidananda Panda; Pam R. Taub. 2019. "Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome." Cell Metabolism 31, no. 1: 92-104.e5.
Type 2 diabetes mellitus and congestive heart failure are highly prevalent diseases with significant morbidity and mortality. These 2 diseases often occur concurrently because of shared risk factors such as coronary artery disease, and also because type 2 diabetes mellitus has direct cardiotoxic effects. Type 2 diabetes mellitus likely has a causative role in the development and prognosis of patients with heart failure. Optimal prevention and treatment of type 2 diabetes mellitus and heart failure likely involves identifying and treating their shared pathophysiologic features. Novel drug therapies, such as sodium-glucose co-transporter 2 inhibitors, offer an exciting potential to better understand the relationship between type 2 diabetes mellitus and heart failure, and may prove to have beneficial effects on cardiovascular outcomes in patients affected by these diseases.
Michael J. Wilkinson; Adena Zadourian; Pam R. Taub. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. The American Journal of Cardiology 2019, 124, S3 -S11.
AMA StyleMichael J. Wilkinson, Adena Zadourian, Pam R. Taub. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. The American Journal of Cardiology. 2019; 124 ():S3-S11.
Chicago/Turabian StyleMichael J. Wilkinson; Adena Zadourian; Pam R. Taub. 2019. "Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship." The American Journal of Cardiology 124, no. : S3-S11.
Type 2 diabetes mellitus and congestive heart failure are highly prevalent diseases with significant morbidity and mortality. These 2 diseases often occur concurrently because of shared risk factors such as coronary artery disease, and also because type 2 diabetes mellitus has direct cardiotoxic effects. Type 2 diabetes mellitus likely has a causative role in the development and prognosis of patients with heart failure. Optimal prevention and treatment of type 2 diabetes mellitus and heart failure likely involves identifying and treating their shared pathophysiologic features. Novel drug therapies, such as sodium-glucose co-transporter 2 inhibitors, offer an exciting potential to better understand the relationship between type 2 diabetes mellitus and heart failure, and may prove to have beneficial effects on cardiovascular outcomes in patients affected by these diseases.
Michael J. Wilkinson; Adena Zadourian; Pam R. Taub. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. The American Journal of Medicine 2019, 132, S3 -S12.
AMA StyleMichael J. Wilkinson, Adena Zadourian, Pam R. Taub. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. The American Journal of Medicine. 2019; 132 (10):S3-S12.
Chicago/Turabian StyleMichael J. Wilkinson; Adena Zadourian; Pam R. Taub. 2019. "Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship." The American Journal of Medicine 132, no. 10: S3-S12.
Objective: To examine resting and postprandial peripheral protease activity in healthy controls and individuals with type 2 diabetes mellitus (T2DM) and pre-T2DM. Methods: Individuals with T2DM or pre-T2DM and healthy controls (mean age 55.8 years) were studied before and for a span of 300 minutes following a single high-calorie McDonald's breakfast. Metalloproteases-2/-9 (MMP-2/-9), elastase, and trypsin activities were assessed in whole blood before and following the meal using a novel high-precision electrophoretic platform. Also assessed were circulating levels of inflammatory biomarkers and insulin receptor density on peripheral blood mononuclear cells (PBMCs) in relationship to protease activity. Results: Premeal MMP-2/-9 and elastase activity levels in T2DM and in pre-T2DM participants were significantly elevated as compared to controls. The T2DM group showed a significant increase in elastase activity 15 minutes after the meal; elastase activity continued to increase to the 30-minute time point (p < 0.01). In control participants, MMP-2/-9, elastase, and trypsin were significantly increased at 15 minutes after the meal (p < 0.05) and returned to premeal values within a period of approximately 30 to 60 minutes post meal. PBMCs incubated for 1 hour with plasma from T2DM and pre-T2DM participants had significantly lower levels of insulin receptor density compared to those incubated with plasma from control participants (p < 0.001). Conclusions: The results of this study suggest that individuals with T2DM and pre-T2DM have higher resting systemic protease activity than nonsymptomatic controls. A single high-calorie/high-carbohydrate meal results in further elevations of protease activity in the systemic circulation of T2DM and pre-T2DM, as well as in healthy controls. The protease activity in turn can lead to a downregulation of insulin receptor density, potentially supporting a state of insulin resistance.
Augusta E. Modestino; Elaine A. Skowronski; Chris Pruitt; Pam R. Taub; Karen Herbst; Geert W. Schmid-Schönbein; Michael J. Heller; Paul J. Mills. Elevated Resting and Postprandial Digestive Proteolytic Activity in Peripheral Blood of Individuals With Type-2 Diabetes Mellitus, With Uncontrolled Cleavage of Insulin Receptors. Journal of the American College of Nutrition 2019, 38, 485 -492.
AMA StyleAugusta E. Modestino, Elaine A. Skowronski, Chris Pruitt, Pam R. Taub, Karen Herbst, Geert W. Schmid-Schönbein, Michael J. Heller, Paul J. Mills. Elevated Resting and Postprandial Digestive Proteolytic Activity in Peripheral Blood of Individuals With Type-2 Diabetes Mellitus, With Uncontrolled Cleavage of Insulin Receptors. Journal of the American College of Nutrition. 2019; 38 (6):485-492.
Chicago/Turabian StyleAugusta E. Modestino; Elaine A. Skowronski; Chris Pruitt; Pam R. Taub; Karen Herbst; Geert W. Schmid-Schönbein; Michael J. Heller; Paul J. Mills. 2019. "Elevated Resting and Postprandial Digestive Proteolytic Activity in Peripheral Blood of Individuals With Type-2 Diabetes Mellitus, With Uncontrolled Cleavage of Insulin Receptors." Journal of the American College of Nutrition 38, no. 6: 485-492.
Postural orthostatic tachycardia syndrome (POTS) is a debilitating disease that predominantly affects young women. It is a multifactorial disorder that is characterized by severe tachycardia and orthostatic intolerance. Patients with POTS experience a variety of cardiac, neurological, and immunological symptoms that significantly reduce quality of life. In this review, a comprehensive framework is provided to aid in helping identify and treat patients with POTS. Given its heterogenous nature, it is crucial to understand each component of POTS in relation to one another instead of distinct parts. The framework highlights the overlap among the five main subtypes of POTS based on its pathophysiology (neuropathic, hypovolemic, primary hyperadrenergic, joint-hypermobility-related, and immune-related). Emphasis is placed on incorporating a multidisciplinary approach when treating patients with POTS, especially with a new focus towards immunotherapy. Although research has advanced our knowledge of POTS, there is still a critically unmet need to further our understanding and provide patients with the relief they need.
Adena Zadourian; Taylor Doherty; Iwona Swiatkiewicz; Pam R. Taub. Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management. Drugs 2018, 78, 983 -994.
AMA StyleAdena Zadourian, Taylor Doherty, Iwona Swiatkiewicz, Pam R. Taub. Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management. Drugs. 2018; 78 (10):983-994.
Chicago/Turabian StyleAdena Zadourian; Taylor Doherty; Iwona Swiatkiewicz; Pam R. Taub. 2018. "Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management." Drugs 78, no. 10: 983-994.